LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Home・Stock List・Emergent BioSolutions Inc

Emergent BioSolutions Inc

Closed

SectorHealthcare

8.02 -1.35

Buy Sell

Overview

Share price change

24h

Current

Min

7.95

Max

8.25

Key metrics
By Trading Economics
Income	61M 6.8M
Sales	7.4M 156M
P/E Sector Avg	8.634 51.415
EPS	0.21
Profit margin	4.356
Employees	900
EBITDA	28M 35M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+51.13% upside

Dividends
By Dow Jones
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	47M 462M
Previous open	9.37
Previous close	8.02

News Sentiment

By Acuity

78%

22%

315 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

4.95 / N/A Support & Resistance

Emergent BioSolutions Inc Chart

Past performance is not a reliable indicator of future results.

Related News

18 May 2026, 23:10 UTC

Hot Stocks

Stocks to Watch: Agilysys, XP

18 May 2026, 18:44 UTC

Major Market Movers

Claritev Shares Recover After Comments About DOJ

18 May 2026, 23:55 UTC

Earnings

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 May 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 May 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 May 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 May 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 May 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 May 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 May 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 May 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 May 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

18 May 2026, 20:25 UTC

Earnings

Correct: XP 1Q Total Client Assets BRL1.53T

18 May 2026, 20:23 UTC

Earnings

XP 1Q Total Client Assets BRL1.53B

18 May 2026, 20:19 UTC

Earnings

XP 1Q Adj EPS BRL2.49 >XP

18 May 2026, 20:19 UTC

Earnings

XP 1Q Rev BRL4.73B >XP

18 May 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 May 2026, 19:00 UTC

Earnings

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 May 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 May 2026, 18:17 UTC

Market Talk

Acquisitions, Mergers, Takeovers

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 May 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 May 2026, 16:57 UTC

Acquisitions, Mergers, Takeovers

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 May 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18 May 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 May 2026, 16:54 UTC

Acquisitions, Mergers, Takeovers

Vinci Doesn't Set Out Financial Details of Deal

18 May 2026, 16:50 UTC

Acquisitions, Mergers, Takeovers

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 May 2026, 16:49 UTC

Acquisitions, Mergers, Takeovers

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 May 2026, 16:49 UTC

Acquisitions, Mergers, Takeovers

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 May 2026, 16:48 UTC

Acquisitions, Mergers, Takeovers

Vinci Buys Canada's Modern Group of Companies

Peer Comparison

Price change

Emergent BioSolutions Inc Forecast

Price Target

By TipRanks

51.13% upside

12 Months Forecast

Average 12 USD 51.13%

High 12 USD

Low 12 USD

Based on 1 Wall Street analysts offering 12 month price targets forEmergent BioSolutions Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Emergent BioSolutions Inc - Dist in the past 3 months.

Technical Score

By Trading Central

4.95 / N/ASupport & Resistance

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

315 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.